open science

Podcast brought to you by: Geschickten Biosciences the world’s first biology knowledge discovery services company focused on democratizing NGS data analyses. To manage, analyze and visualize your NGS data please login to interpretomics.co

Kevin Lustig, PhD, CEO, Assay Depot Bio and Contact Info

Opening up the World of Drug Discovery: Kevin Lustig, Assay Depot from mendelspod on Vimeo.

Listen (4:33) Assay Depot

Listen (6:33) What took so long to get an Amazon for the life sciences?

Listen (7:18) Empowering individual scientists

Listen (3:33) What is a programmable lab?

Listen (5:55) Drug development from the beach at Waikiki

Listen (2:07) Open Science Challenge

As the pharma industry moves toward more outsourcing and virtual business structures, a new online exchange has emerged as a popular platform for life science transactions. AssayDepot.com has been called by Atul Butte, bioinformatics professor at Stanford, a Home Depot for science. In today's show we talk with the co-founder and CEO of Assay Depot, Kevin Lustig. Originally Kevin and his colleague created the site to complement what was going to be a new CRO in San Diego. Soon they realized the site itself, with features borrowed from Amazon, Kayak, and Google, offered a greater business opportunity than another CRO. Kevin talks about the platform and its various features and at large about new trends in pharma.

Podcast brought to you by: Assay Depot - the world's largest cloud-based Research Exchange for pharmaceutical research services.

Guest:

Bernard Munos, Founder of InnoThink Bio and Contact Info

Listen (5:25) What to do to correct poor situation?

Listen (4:30) Open source R & D

Listen (4:28) Critical mass becomes one human brain

Listen (8:40) Issue of IP and other challenges for open model

Listen (5:07) Examples of open source R & D

Listen (9:53) Is this a personal calling?

Listen (4:31) Is your message taking hold with big pharma?

Listen (5:20) When it comes to drug R & D, the bolder the better

Bernard Munos is the founder of InnoThink, a partnership dedicated to bringing innovation to the pharmaceutical industry. In this second of a two-part interview, Bernard presents his solutions for radically improving the way drug development is done. Bernard, who calls himself an 'apostle of innovation', is a proponent of radical disruption, specifically going to an open source model of R&D, with smaller, even virtual companies. Speaking out after a 30 year career at Lilly, Bernard is not constrained by a corporate boss or short-sighted shareholders. He's calling for big change, "the bolder the better."

Chatting with Bernard at a local winery in Los Gatos

Podcast brought to you by: Assay Depot - the world's largest cloud-based Research Exchange for pharmaceutical research services.

Guest:

Bernard Munos, Founder of InnoThink Bio and Contact Info

Listen (6:24) Pharma industry edging toward irrelevance

Listen (5:54) All industries go through period of disruption

Listen (8:33) What is behind the terrible outlook?

Listen (4:21) A change in values

Listen (3:46) Why is Bernard Munos speaking out?

Listen (6:46) Dashed hopes for big change at Eli Lilly

Bernard Munos is the founder of InnoThink, a partnership dedicated to bringing innovation to the pharmaceutical industry. Prior to this he spent 30 years in various roles at Eli Lilly, including market research and corporate development and business strategy. During his last 10 years at Lilly, he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model. Bernard presents his findings at numerous conferences around the world and is considered a leader in pharma innovation.

He studied at Stanford University, UC Davis, and the Paris Institute of Technology for Life, Food, and Environmental Sciences. We’re pleased to have him for a two part show to talk about the pharma industry and his ideas for fixing it.

Chatting with Bernard at a local winery in Los Gatos

Podcast Sponsor: Ingenuity - iReport, the fastest and most accurate way to get biological meaning from your expression data. Upload your data and get a free iReport analysis summary at www.ingenuity.com/get iReport/

Guest:

Anne Wojcicki, CEO, 23andMe Bio and Contact Info

Listen (8:18) Influencers

Listen (1:14) What were you doing when the human genome was first sequenced?

Listen (2:16) 23andMe, an engine for transforming healthcare

Listen (4:21) Questions from the mendelspod audience

Listen (4:26) Favorite example of a customer

Listen (0:56) Important to win over scientific community

Listen (3:41) Personal questions are a distraction

Anne Wojcicki is the co-founder and CEO of the consumer genomics company, 23andMe. Prior to founding the company in 2006, Anne worked in healthcare investing ,focused primarily on biotech companies. Anne graduated from Yale with a Bachelor of Science in Biology. Under Anne's leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Presently, 23andMe has built one of the world's largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once. Getting access to and understanding her own genetic information had always been one of Anne’s ambitions.

Podcast Sponsor: Assay Depot- The world's largest cloud-based Research Exchange for pharmaceutical research services. Assay Depot is currently sponsoring the Open Science Challenge. Submit your research plan to assaydepot.com, for a chance to win from the $10,000 prize pool. Guest: Elizabeth Iorns, CEO, Science Exchange Bio and Contact Info Listen (4:21) What is Science Exchange? Listen (3:06) Who are the providers? Listen (1:33) Advantages of being vendorized Listen (3:02) Will this send jobs overseas? Listen (11:06) Participation in Y Combinator Listen (3:55) Is this the future? Listen (1:38) New site trends Outsourcing is more and more the trend in bio these days. In an effort to reduce the huge cost of drug development, big pharma is teaming up with universities and small biotech. One hears of new virtual companies set up relying completely on a network of partners, much like NuMedii, a company we recently profiled. Yet there are challenges that come with outsourcing. Elizabeth Iorns and her colleagues have started scienceexchange.com to address just those challenges. The site is being referred to as an eBay for science. A former researcher herself at the University of Miami, Elizabeth joins us today to tell us about this new marketplace and how it solves outsourcing challenges.

Podcast Sponsor: Ingenuity- iReport: The fastest way to get meaning from your expression data

Listen (3:50) Steve Burill: New Model for Big Pharma

Listen (7:06) Dan Vorhaus: The Myriad Case

Listen (3:36) Russ Altman: Personal Genomics and Patent Law

Listen (3:43) Mike Snyder: Million Dollar Interpretation

Listen (2:50) Howard McLeod: PGENI

Listen (2:08) Jonathan Eisen: Why Open Science?

Listen (3:12) George Church: Scientists and the Public

Listen (4:25) Ron Davis: Fit Between University and Industry

Listen (3:01) Greg Scott-Will China Soon Have a Steve Jobs?

As we approach the last day of 2011, we thought we’d look back and bring you highlights of the year, the very best of mendelspod. Included in today’s show are snippets from industry leaders on personalized medicine, the evolution of big pharma, gene patents, and thoughts on open science.

NOTE: It’s important to acknowledge that mendelspod has been made possible through the generous support of our sponsors throughout the year. We thank all of them for their partnership. We wish them and all of you a very happy holiday.

Podcast Sponsor: Ingenuity - The fastest way to obtain biological meaning from your expression data. Get a free iReport

Guest:

Dr. Ron Davis, Director, Stanford Genome Technology Center, Bio and Contact Info

Listen (2:04) Money from prize to research chronic fatique syndrome

Listen (6:48) Bringing engineers to clinical medicine

Listen (8:04) Fit between university lab and commercial development

Listen (5:47) Fan of targeted analysis of genome

Listen (3:17) Should scientists engage general public?

Listen (6:32) What about technology drives you?

Listen (3:29) Is NIH funding academic welfare?

Listen (11:18) Thoughts on 'open science'

Listen (1:33) How do you characterize yourself?

We’re delighted to welcome to mendelspod a veteran of the life science arena, Dr. Ron Davis. He’s the director of the Stanford Genome Technology Center and winner of this year’s Gruber Genetics Prize. The prize was presented to Ron a couple weeks ago at the ASHG ho-down in Montreal. Ron has been a leader in the area of genomics and high throughput biochemical techniques and been involved in the spinoff of multiple start-up companies from his lab at Stanford. He’s a co-founder of ParAllele, a company later purchased by Affymetrix and is former advisor to Ion Torrent, whose semiconductor sequencing technology is dramatically reducing the cost of sequencing.

Ron shares with us some of the current technology that he's working on and talks about how he goes about it. In a very candid interview, Ron talks about issues around NIH funding and the growing 'open science' movement.

Podcast Sponsor:

Traitwise.com, Phenotypic surveys

Guests:

Joseph Jackson, Organizer, Open Science Summit Bio and Contact Info

Listen (3:37) Why open science for you?

Listen (6:03) 2nd Open Science Summit

Listen (8:49) The future (or end) of IP

Listen (8:02) Does open science mean free science?

Listen (6:37) Put failures online as well

Listen (5:09) A matter of when to publish

Listen (4:50) Obstacles to open science

Dr. Tomasz Sablinski, Founder, Transparency LS Bio and Contact Info

Listen (9:32) Crowdsourcing clinical trials

Listen (5:20) Company objective

Listen (6:01) Advantages to open method

Listen (3:03) Process

Listen (4:41) Is this the future?

'Open science' is a term frequently used in the life science community today. In an interview with KQED in San Francisco, open science evangelist Joseph Jackson says, “in the long run, open science will transform the way science is done, enhancing the best aspects of science while helping correct potential abuses and distortions." Mr. Jackson is the organizer of the 2nd Open Science Summit taking place in Mountain View CA Oct 22-23. He’s a co-founder of BioCurious, a community lab in Sunnyvale and co founder of LavaAmp, maker of an inexpensive, pocket size pcr machine. I am pleased to have Joseph and Dr. Tomasz Sablinski, a speaker at the conference, on the program today to talk about the upcoming summit.

Podcast Sponsors: IDT - Free Guide to Mutagenesis

Guest: Jonathan Eisen, Ph D, UC Davis Genome Center, Bio and Contact Info

Today we have a special show. In our first video production, we’re coming to you from the UC Davis Genome Center where we’re joined by evolutionary biologist, Dr. Jonathan Esien. Jonathan and his lab here are becoming better known since the release of a paper in February which suggested evidence of a fourth domain to the basic tree of life. What do we mean by 4th domain? We’ll be asking Jonathan that soon. He is this year’s recipient of the Benjamin Franklin Award, and we’re pleased he had us to his lab.